Search results with tag "Codox"
R-CODOX-M / R-IVAC - NSSG - Haematology
nssg.oxford-haematology.org.ukR-CODOX-M / R-IVAC Authorised by Lymphoma lead Dr Graham Collins Date: May 2018 Published: September 2008 Reviewed: May 2018 Updated: Aug 2020 Review: May 2022 Version 4.4 1 of 9 R-CODOX-M / R-IVAC INDICATION Burkitt lymphoma, ‘double hit’ lymphoma or high IPI diffuse large B-cell lymphoma. TREATMENT INTENT Curative. PRE-ASSESSMENT 1.
バーキットリンパ腫と類縁疾患
www.harasanshin.or.jpG.M.Mead et al. Ann Oncol 2002; 13: 1264-1274 LY06試験(UKLGリスク分類) Low Risk CODOX-M療法 3コース High Risk CODOX-M/IVAC 交代療法 4コース N = 52 Median age 38 CR 76.5% 2yrEFS 64.6% 2yrOS 72.8% High risk 2yrEFS 60% 2yrOS 70%
がん化学療法承認レジメン一覧
www.shimane-u-gankyo.jpR-CODOX-M 腫瘍・血液内科 282 Burkitt / Burkitt-like lymphoma キロサイドN【Ara-C】 イホマイド【IFM】 エトポシド【VP-16】 キロサイド【Ara-C】髄注 メソトレキセート【MTX】髄注 IVAC 腫瘍・血液内科
PROPHYLAXIS GUIDELINES FOR THE ADULT …
www.med.umich.eduCODOX-M/IVAC Levofloxacin 500 mg PO daily Fluconazole 200 mg PO daily TMP-SMX (Bactrim) DS 3 times weekly Antifungal: (hold through methotrexate admission until level <0.1 µM) Acyclovir 400 mg PO BID Antibacterial: Beginning with Part B of regimen and continued throughout all chemotherapy cycles Send Rx for patient to start at discharge and ...